Alpha Spike Protein
Lab Reagents
Human IgG antibody Laboratories manufactures the alpha spike protein reagents distributed by Genprice. The Alpha Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Alpha products are available in stock. Specificity: Alpha Category: Spike Group: Protein
Rabbit Anti-MERS-CoV Spike protein S2 (726-1296 a.a) IgG, aff pure |
|||
MERSS22-A | Alpha Diagnostics | 100 ul | EUR 578.4 |
Recombinant (E. coli) Hepatitis virus (MHV/Coronavirs) Spike Protein S1 protein control for Western blot |
|||
MHVS14-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Mouse monoclonal Anti-MERS-CoV Spike protein S2 (726-1296 a.a) IgG, aff pure |
|||
MERSS21-M | Alpha Diagnostics | 100 ul | EUR 578.4 |
Mouse Anti-Mouse Hepatitis virus (MHV/Coronavirs) Spike Protein S1 antibody negative control serum |
|||
MHVS11-MNC | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Anti-Mouse Hepatitis virus (MHV/Coronavirs) Spike Protein S1 antibody positive control serum |
|||
MHVS11-MPC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Mouse Hepatitis virus (MHV/Coronavirs) Spike Protein S1 antibody negative control serum |
|||
MHVS12-RNC | Alpha Diagnostics | 1 ml | EUR 270 |
Rat Anti-Mouse Hepatitis virus (MHV/Coronavirs) Spike Protein S1 antibody positive control serum |
|||
MHVS12-RPC | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Monoclonal Anti-Porcine epidemic diarrhea virus Spike protein S1 (PEDV-S1) IgM, unlabeled |
|||
PEDV13-M | Alpha Diagnostics | 100 ul | EUR 578.4 |
SARS-CoV-2 Spike P681H Antibody (Alpha, Mu Variant) |
|||
9359-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein. |
SARS-CoV-2 Spike P681H Antibody (Alpha, Mu Variant) |
|||
9359-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: In September of 2020 a new lineage of SARS-CoV-2, known as B.1.1.7, was discovered in the United Kingdom. This lineage was found to have developed 14 lineage-specific amino acid replacements and 3 deletions prior to its discovery. The transmission of UK variant (B.1.1.7 lineage) was increased at least 50%. Increased severity and higher death rate were also found in UK variant. UK variant will not affect the effectiveness of COVID19 vaccine. One of the mutations associated with this lineage is a N501Y in the spike protein of the virus. It is believed that this mutation is able to increase the spike protein's affinity for the host ACE2 receptor and it has been associated with increased infectivity and virulence. B.1.1.7 viruses have also been shown to have a P681H in the cleavage site of spike protein. This location is one of the residues that make up the furin cleavage site between S1 and S2 in spike protein. |
SARS Spike RBD Recombinant Protein |
|||
10-211 | ProSci | 0.1 mg | EUR 651.3 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
MERS Spike S1 Recombinant protein |
|||
39-102 | ProSci | 0.1 mg | EUR 556.8 |
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis. |
SARS-CoV spike protein Antibody |
|||
abx023139-100ug | Abbexa | 100 ug | EUR 1028.4 |
SARS-CoV spike protein Antibody |
|||
abx023143-100ug | Abbexa | 100 ug | EUR 1028.4 |
SARS Spike Peptide |
|||
3219P | ProSci | 0.05 mg | EUR 197.7 |
Description: (NT) SARS Spike peptide |
SARS Spike Peptide |
|||
3525P | ProSci | 0.05 mg | EUR 197.7 |
Description: (CT) SARS Spike peptide |
SARS Spike Antibody |
|||
24216-100ul | SAB | 100ul | EUR 468 |